Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on innovative therapies for neurodegenerative and metabolic disorders, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage—an area Durkacz said remains unmet by current treatments.
Durkacz also highlighted the company’s commercial alcohol metabolism product, unbuzzd™, which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. The product is sold through Unbuzzd Wellness Inc., a company in which Quantum retains a 19.84% ownership stake (as of March 31, 2026) and receives royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of rights to develop similar products for pharmaceutical and medical uses.
Looking ahead, Durkacz emphasized the upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis—in preclinical models.
The news matters because Quantum BioPharma is advancing a potential therapy for multiple sclerosis that could address a significant unmet need. Current treatments primarily manage symptoms or slow progression, but Lucid-MS targets the underlying nerve damage and myelin repair. If successful in Phase 2 trials, it could offer a novel approach to treating mobility loss in MS patients, impacting the estimated 2.8 million people worldwide living with the disease.
Additionally, the unbuzzd™ product provides a revenue stream through royalties and ownership, potentially generating substantial income if sales grow. The agreement includes a $250 million threshold before royalty rates decrease, indicating significant commercial expectations.
For investors, the company’s progress in clinical trials and commercial sales are key indicators of future value. The full press release is available at https://ibn.fm/8sLvp. More information about the company can be found in its newsroom at https://ibn.fm/QNTM.
Quantum BioPharma is dedicated to building a portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it focuses on research and development of Lucid-MS. The company’s strategy combines clinical-stage drug development with commercial products, aiming to create multiple value drivers.
The upcoming Phase 2 trial will be closely watched by the medical community and investors alike, as positive results could position Lucid-MS as a breakthrough therapy. Meanwhile, unbuzzd™ continues to generate revenue and market presence, providing near-term financial support.
